was only performed in the European ancestry subset of COGA). None of the interactions between the schizophrenia PRS and duration of daily cannabis use passed our significance threshold of α = 9.8e−4 (P > .42). The same was true for interactions between the schizophrenia PRS and age at first cannabis use (P > .01) and between the schizophrenia PRS and CUD diagnosis, although the interaction effect between the PRS and CUD on any cannabis-related experience was the strongest (P > .003; supplementary table 5).
